NBRV

Nabriva Therapeutics PLC

Price

return (12m)

p/e

0.00

p/bv

0.00

DIVIDEND YIELD

0.00%

NBRV price

Nabriva Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*The amount considers the reinvestment of dividends.

Return on Investment NBRV

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals NBRV

Valuation

P/E

0.00

Sector 0.84

Industry -1.42

P/BV

0.00

Sector 1.82

Industry 1.25

P/Revenue (PSR)

Sector 1.48

Industry 2.13

EV/EBITDA

0.54

Sector -43.66

Industry -35.45

EV/EBIT

0.54

Sector -47.57

Industry -38.86

P/EBITDA

Sector -31.25

Industry -21.12

P/EBIT

Sector -42.58

Industry -25.59

P/Total Assets

Sector 0.82

Industry 0.70

P/Net Current Assets

Sector -23.77

Industry -59.56

P/Working Capital

Sector -3.73

Industry -1.93

EPS

-29.82

Sector -0.70

Industry -1.22

BVPS

1.23

Sector 4.50

Industry 2.78

Efficiency

Gross Margin

-5.98%

Sector 49.32%

Industry 49.70%

EBITDA Margin

-213.92%

Sector -305.63%

Industry -17,123,193.33%

EBIT Margin

-100.00%

Sector -19.73%

Industry -25.36%

Net Profit Margins

-100.00%

Sector -23.90%

Industry -27.40%

Asset Turnover

0.33

Sector 0.13

Industry 0.06

Profitability

ROE

-2,428.27%

Sector -24.30%

Industry -38.97%

ROA

-251.73%

Sector -24.50%

Industry -49.14%

ROIC

Sector -584.46%

Industry -1,072.15%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 1.92

Industry 2.55

Net Debt / EBITDA

0.54

Sector -23.10

Industry -8.80

Net Debt / EBIT

0.54

Sector -17.84

Industry -36.75

Net Debt / Equity

-3.67

Sector -0.68

Industry -1.16

Gross Debt / Equity

0.10

Sector -0.72

Industry -0.54

Equity/Assets

0.10

Sector 0.46

Industry 0.52

Liabilities/Assets

0.90

Sector 0.50

Industry 0.47

Growth

5Y Revenue CAGR

6.97%

Sector -

Industry -

5Y Earnings CAGR

10.09%

Sector -

Industry -

Fundamentals NBRV

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
NBRV Nabriva Therapeutics PLC	$0.00	-	0.00%	0.00	0.00	-2,428.27%	-100.00%
LLY Eli Lilly and Compay	$1,249.76	56.65%	0.53%	42.13	33.21	78.84%	33.53%
SNY Sanofi	$39.81	-18.25%	4.38%	3.78	0.70	18.43%	14.25%
GSK GlaxoSmithKline PLC	$49.36	16.30%	3.58%	15.38	4.34	28.24%	14.54%
CRMD CorMedix Inc.	$7.48	-26.52%	0.00%	3.04	1.23	40.62%	40.49%
AMPH Amphastar Pharmaceuticals Inc.	$25.97	9.21%	0.00%	14.41	1.47	10.23%	10.76%
RDY Dr. Reddy's Laboratories Ltd.	$13.05	-9.04%	0.64%	29.37	2.65	9.03%	10.14%
JNJ Johnson & Johnson	$252.71	34.46%	2.08%	29.04	7.19	24.76%	21.48%
ISRG Intuitive Surgical Inc.	$431.59	-3.26%	0.00%	48.53	8.32	17.15%	28.44%
NVS Novartis AG	$150.19	16.49%	2.05%	22.56	6.86	30.41%	23.29%
TMO Thermo Fisher Scientific Inc.	$673.79	25.46%	0.27%	36.53	4.83	13.22%	15.04%
ABT Abbott Laboratories	$103.75	-16.91%	2.53%	31.55	3.35	10.61%	11.65%
MDT Medtronic PLC	$92.84	0.14%	3.02%	23.20	2.39	10.29%	13.93%
CVS CVS Health Corporation	$91.15	14.82%	2.89%	24.09	1.47	6.12%	1.18%
BSX Boston Scientific Corp.	$44.56	-55.10%	0.00%	17.83	2.63	14.73%	17.49%
TMDX TransMedics Group Inc.	$72.35	-38.50%	0.00%	16.36	4.79	29.28%	22.69%
IDXX IDEXX Laboratories Inc.	$556.87	-12.36%	0.00%	38.87	27.47	70.67%	25.03%
RMD ResMed Inc.	$239.43	-9.75%	1.03%	22.76	5.27	23.13%	26.94%
DHR Danaher Corporation	$224.14	8.20%	0.63%	40.42	3.08	7.61%	15.95%
HCA HCA Healthcare Inc.	$454.64	7.19%	0.66%	14.90	-31.76	-213.15%	8.77%
COHR Coherent Inc.	$240.39	106.61%	0.00%	57.23	4.10	7.16%	11.31%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

NBRV - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Nabriva Therapeutics

Nabriva Therapeutics PLC

Average Investor10 user rating

4.0 (0 people)

United States

9 years

Founded: 2017

2017

Time since IPO - 9 years

72

Employees

Nabriva Therapeutics PLC (United States) is listed on the Nasdaq and has a market capitalization of $-, with shareholders equity totaling $3.29 million.

The company employs approximately 72 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Nabriva Therapeutics PLC reported $39.22 million in revenue, generating net income of $-79.96 million.

Key financial metrics include a P/E ratio of 0.00, a price-to-book (P/B) ratio of 0.00, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker NBRV.

Market cap

Net worth

$3.29 million

$3,293,000.00

Assets

$31.77 million

$31,765,000.00

Total Shares Outstanding

2.68 million

2,681,000

Average Daily Trading Volume

$24.67 Thousand

$24,673.92

Sector

Health

Industry

Pharmaceutical Products

NBRV

NBRV revenue and profits

Financial Results NBRV

DRAG THE FRAME TO SEE MORE DATA

NBRV cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$91.15 14,82% (12M)

P/E

24.09

2.89%

ROE

6.12%

P/BV

1.47

CI - Cigna

$296.71 1,38% (12M)

P/E

11.63

2.05%

ROE

16.04%

P/BV

1.87

CNC - Centene

$68.16 93,24% (12M)

P/E

-6.73

0.00%

ROE

-22.53%

P/BV

1.52

HUM - Humana

$411.55 52,12% (12M)

P/E

39.10

0.85%

ROE

6.63%

P/BV

2.59

SNY - Sanofi

$39.81 --18,25% (12M)

P/E

3.78

4.38%

ROE

18.43%

P/BV

0.70

JNJ - Johnson & Johnson

$252.71 34,46% (12M)

P/E

29.04

2.08%

ROE

24.76%

P/BV

7.19

LLY - Eli Lilly

$1,249.76 56,65% (12M)

P/E

42.13

0.53%

ROE

78.84%

P/BV

33.21

HCA - HCA Healthcare

$454.64 7,19% (12M)

P/E

14.90

0.66%

ROE

-213.15%

P/BV

-31.76